A potentially effective drug for patients with recurrent glioma: sermorelin.

Retrospective transcriptomic analysis and in vitro cell line study

“This study was designed to screen out effective drugs for recurrent gliomas based on the transcriptomics data.”

Glioma patients (primary and recurrent) and human glioblastoma cell lines (U87, LN229)

“A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.”

1,018 glioma patients (325 discovery, 693 validation) and 4,865 drugs screened

“A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study.”

Sermorelin was identified as the most sensitive drug for recurrent glioma patients based on Drug Resistant Scores.

“After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin.”

Sermorelin sensitivity was associated with high-grade, IDH-wildtype, and 1p/19q non-codeletion status, and linked to cell cycle blocking.

“Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status.”

Sermorelin was negatively correlated with immune checkpoints and M0 macrophages, and its prognostic value was independent of adjuvant treatment.

“Moreover, sermorelin was also related to the immune system process and negatively regulated immune checkpoints and M0 macrophages.”